Start-Up News May 2007
Executive Summary
New device treatmetns for epilepsy, obesity management on a larger scale.
You may also be interested in...
Seizure Desist: Neurostim Companies Pursue Alternative Treatments for Epilepsy
The rise of interest in neurostimulation and neuromodulation approaches is leading venture capitalists and large medical device companies to develop devices to prevent or block seizures. The devices would be used primarily on patients who don't respond to drugs for epilepsy.
The Skinny on Obesity Products
The total obesity products market, including drugs and device, is projected to reach more than $1.6 billion by 2010, growing at a compound annual rate of 36.1%. Success in this arena will depend on whether emerging drugs and devices can live up their hype and deliver the results needed to achieve regulatory approval and marketplace acceptance.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.